Noxopharm Ltd. · ASX:NOX
Noxopharm — Corporate Update (March 2018)
27 slides from Noxopharm's corporate update, Mar 12, 2018
Slide 1: Corporate Presentation: Post-Interim Clinical Data Release
For personal use only Date: 12 March 2018 Sydney, Australia ASX Limited ASX: NOX 20 Bridge Street Noxopharm Limited SYDNEY NSW 2000 ABN 50 608 966 123 Registered Office and CORPORATE PRESENTATION: POST- Operational Office: Suite 3, Level 4 INTERIM CLINICAL DATA RELEASE 828 Pacific Highway Gordon NSW
Slide 2: About Noxopharm / Forward Looking Statements
About Noxopharm Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to sensitise cancer cells to radiotherapy and chemotherapy. NOX66 is the first pipeline product, with later generation drug candidates
Slide 3: A Clinical Oncology Company
For personal use only A CLINICAL ONCOLOGY COMPANY March 2018 1
Slide 4: Our aim
Noxopharm For personal use only Our aim. To bring to market: • the first approved radio-enhancing drug • that will increase the effectiveness of radiotherapy • including the possibility of obtaining abscopal responses • and become a standard-of-care in cancer therapy. 2
Slide 5: NOX66 Lipid-protected form of idronoxil
Noxopharm For personal use only NOX66 Lipid-protected form of idronoxil 3
Slide 6: About Idronoxil
Noxopharm ABOUT IDRONOXIL For personal use only Multiple anti-cancer actions 1. Inhibits DNA repair inhibits PARP-1, topoisomerases 1 and 2 2. Promotes anti-tumour immunity Increases NK (natural killer) cell activity 4
Slide 7: Oral Idronoxil vs NOX66 suppository (LIPROSE technology)
Noxopharm Oral Idronoxil NOX66 suppository For personal use only LIPROSE Technology Subject to Drug protected metabolism from metabolism 95-100% of drug Protected drug inactivated remains active 5
Slide 8: Three clinical NOX66 programs
Noxopharm Three clinical NOX66 programs For personal use only 1. Enhance external beam radiotherapy DARRT program prostate cancer rare cancers 2. Enhance intravenous radiotherapy LUPIN program prostate cancer 3. Enhance chemotherapy CEP program common cancers 6
Slide 9: DARRT: Direct and Abscopal Response to Radiotherapy
Noxopharm DARRT program For personal use only Direct and Abscopal Response to Radiotherapy Objectives: irradiated tumours to respond better (direct response) non-irradiated tumours to respond as well (abscopal response) External beam radiotherapy 7
Slide 10: DARRT: Metastatic cancer too extensive for radiotherapy
Noxopharm DARRT program For personal use only Metastatic cancer too extensive for radiotherapy CT/MRI scans identifies tumours > 2mm diameter. (Fig. A). These can be irradiated. But majority of secondary cancers generally much smaller than this and scattered throughout the body. (Fig. B). Whole of b
Slide 11: DARRT: Direct response to radiotherapy
Noxopharm DARRT program For personal use only DIRECT Response to Radio-Therapy Radiotherapy applied to large Shrinkage of irradiated Direct radio-sensitising effect tumours tumours for pain relief 9
Slide 12: DARRT: Direct response to radiotherapy with NOX66
Noxopharm DARRT program For personal use only DIRECT Response to Radio-Therapy + NOX66 Radiotherapy applied to large Shrinkage of irradiated Seeking complete remission of Direct radio-sensitising effect Direct radio-sensitising irradiated tumours effect tumours for pain relief tumours 10
Slide 13: DARRT program: Abscopal response
Noxopharm DARRT program ABSCOPAL Response For personal use only Exposed tumours respond ✙ Non-exposed tumours also respond + + NOX66 NOX66 Seeking Direct complete remission radio-sensitising effectof Low-dose radiotherapy Abscopal response irradiated tumours 11
Slide 14: DARRT: Abscopal response
Noxopharm DARRT program For personal use only ABSCOPAL Response Rare – very rare phenomenon Complete – primary AND secondary tumours respond Durable – potentially permanent Unrestricted – range of cancers reportedly involved Short treatment – single course of treatment (7-14 days) Low toxicity – non
Slide 15: DARRT-1 study
Noxopharm DARRT program For personal use only DARRT-1 Phase 1b study. Open, actively recruiting. 24 patients. 9 sites: NZ (1); Georgia (3); Australia (5) Ø Prostate cancer (metastatic castrate-resistant) Ø Patients with multiple (>3) tumours Ø Low dose radiotherapy to 1-2 tumours (5 days) Ø + NOX66
Slide 16: LUPIN: Enhancing intravenous radiotherapy
Noxopharm LUPIN program For personal use only Enhancing intravenous radiotherapy (brachytherapy) Prostate cancer cells express high levels of prostate-specific membrane antigen (PSMA) Antibody made to PSMA. When injected IV, locates and attaches to prostate cancer cells 1 of 2 radioisotopes attached
Slide 17: LUPIN-1 study
Noxopharm LUPIN program For personal use only LUPIN-1 Phase 1b study. Open, recruiting. 24-30 patients (4 currently being treated) St Vincent’s Hospital, Sydney Ø Prostate cancer (metastatic castrate-resistant) Ø 6x monthly injections of 177lutetium-PSMA-617 Ø + NOX66 10 days Ø End-points: safety; m
Slide 18: CEP: Enhancing chemotherapy
Noxopharm CEP program For personal use only Aim 1: to develop a well-tolerated chemotherapy Enhancing chemotherapy regimen that can be used in conjunction with NOX66 + radiotherapy to provide a whole-of-body anti-cancer effect in those patients who do not experience an abscopal response. Aim 2: to d
Slide 19: CEP-1 study
Noxopharm CEP program For personal use only CEP-1 Phase 1b study. Closed. Fully recruited 18 patients 3 Georgian sites Ø Late-stage cancers (breast, ovarian, lung, prostate) Ø 6x monthly treatment cycles Ø NOX66 10 days/carboplatin IV injection Ø End-points: safety; tumour response (RECIST/ECOG Scor
Slide 20: CEP program CEP-1 dosing
Noxopharm CEP program CEP-1 For personal use only Objective: development of a drug regimen capable of providing clinical benefit in patients with late-stage cancer, without being associated with serious toxicity Carboplatin normally given either weekly or every 2, 3 or 4 weeks over a 5-6 month perio
Slide 21: CEP-1 study interim report March 2018
Noxopharm CEP program For personal use only CEP-1 STUDY Interim report 5 March 2018 14 patients underwent NOX66 + carboplatin (AUC 4) treatment/3 months After 3 months: • 1 patient showed partial response (RECIST) • 11 patients showed no disease progression (RECIST) • 2 patients showed disease progr
Slide 22: Comparison of CEP-1 data with immuno-oncology drug data
Noxopharm Comparison of CEP-1 data with immuno- For personal use only oncology drug data • Lung Cancer trial (582 patients evaluated) • Opdivo vs standard of care chemotherapy (Taxotere) • Time to disease progression – 2.3 months (Opdivo) v 4.2 months (Taxotere) • Overall Response Rate – 19% (Opdivo
Slide 23: Moving towards first registration
Noxopharm For personal use only Moving towards first registration Likely registration indication: NOX66 in combination with palliative external beam radiotherapy for the treatment of patients with metastatic cancer (prostate and others) Notes: DARRT-1 Phase 1: Prostate Cancer. External Beam RT • ORP
Slide 24: Where we hope to be in 2018
Noxopharm Where we hope to be in 2018 For personal use only Mid-2018 • Preliminary indication of most likely Phase 3 (registration) clinical indication/trial design End-2018 • Confirmation of Phase 3 registration study/studies • Selection of sites (multi-national) • Investigator meeting held. Protoc
Slide 25: Key metrics
Noxopharm Key metrics ……….. For personal use only Shares outstanding 57M free; 52M escrowed (July 2018) Other 25.3M options Market Cap $130M IPO price $0.20 Last traded $1.20 CEO Cash position $4M (approx.) Directors Other founders8 Others 23
Slide 26: Disclaimer
For personal use only Disclaimer • This presentation has been prepared by Noxopharm Limited a company proposed to be listed as [ASX:NOX] (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to make an offer or
Slide 27: Contact
For personal use only Contact 25